Litcius/Paper detail

Structural basis for inhibition of the AAA-ATPase Drg1 by diazaborine

Michael Prattes, Irina Grishkovskaya, Victor-Valentin Hodirnau, Ingrid Rössler, Isabella Klein, Christina Hetzmannseder, Gertrude Zisser, Christian Gruber, Karl Gruber, David Haselbach, Helmut Bergler

2021Nature Communications26 citationsDOIOpen Access PDF

Abstract

The hexameric AAA-ATPase Drg1 is a key factor in eukaryotic ribosome biogenesis and initiates cytoplasmic maturation of the large ribosomal subunit by releasing the shuttling maturation factor Rlp24. Drg1 monomers contain two AAA-domains (D1 and D2) that act in a concerted manner. Rlp24 release is inhibited by the drug diazaborine which blocks ATP hydrolysis in D2. The mode of inhibition was unknown. Here we show the first cryo-EM structure of Drg1 revealing the inhibitory mechanism. Diazaborine forms a covalent bond to the 2'-OH of the nucleotide in D2, explaining its specificity for this site. As a consequence, the D2 domain is locked in a rigid, inactive state, stalling the whole Drg1 hexamer. Resistance mechanisms identified include abolished drug binding and altered positioning of the nucleotide. Our results suggest nucleotide-modifying compounds as potential novel inhibitors for AAA-ATPases.

Topics & Concepts

Random hexamerBiogenesisNucleotideAAA proteinsRibosome biogenesisATPaseProtein subunitRibosomeBiochemistryChemistryWalker motifsCyclic nucleotide-binding domainCell biologyBiologyATP hydrolysisEnzymeRNAGeneRNA modifications and cancerRNA and protein synthesis mechanismsSignaling Pathways in Disease
Structural basis for inhibition of the AAA-ATPase Drg1 by diazaborine | Litcius